Physician profile
Rozen Gilerman
NPI 1881332757
$496.97
in general payments reported to CMS, 2019-2025
14 companies · $474 in 2025
The $474 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $23.47 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $92.78 | 2025 | Veozah |
| Corcept Therapeutics | $78.47 | 2025 | Korlym |
| Pfizer INC. | $56.88 | 2025 | |
| Axsome Therapeutics, INC. | $41.50 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.32 | 2025 | Xifaxan |
| Dexcom, INC. | $28.35 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $28.01 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Corium, LLC | $27.05 | 2025 | Azstarys |
| Organon LLC | $23.47 | 2023 | Nexplanon |
| Janssen Pharmaceuticals, INC | $23.35 | 2025 | Spravato |
| Novo Nordisk INC | $19.03 | 2025 | Wegovy |
| Abbvie INC. | $17.21 | 2025 | |
| Amgen INC. | $16.53 | 2025 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $15.02 | 2025 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rozen Gilerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.